A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Gilead Sciences
- 20 Jun 2019 Results (n=54) evaluating the safety and efficacy sofosbuvir plus ribavirin in children aged 3 to <12 years, are published in the Hepatology.
- 24 Sep 2018 Status changed from active, no longer recruiting to completed.
- 22 Jun 2018 This trial has been completed in Germany.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History